Establishment of 5-Fluorouracil-resistant canine mammary tumor cell line

• Autorzy: Zhou B. , Zhang D. , Pei S.M. , Zhang K. , Du H.C. , Jin Y.P. , Lin D.G.
• Języki publikacji: EN

Abstrakty

EN

Canine mammary tumors are the most common neoplasms in intact female dogs. The surgery cannot always solve the problem, chemotherapy are recommend to these patients. However, chemotherapy could always fail because of multidrug resistance (MDR). Through stepwise increasing 5-Fluorouracil (5-FU) concentration in the culture medium, a 5-FU-resistant canine mammary tumor cell line CMT7364/5-FU was established to disclose the molecular mechanism of the drug resistance. Cell morphology, cell sensitivity to drugs, growth curves, expression of proteins, and chemo-sensitivity in vivo were compared between the parental cell line and resistant cell line. As compared it to its parental cell line (CMT7364), CMT7364/5-FU showed different morphology, cross-resistant to other chemo-drugs and a prolonged population doubling time (PDT). The drug efflux pump proteins (ABCB1 and ABCG2) in CMT7364/5-FU were up-regulated. In vivo, the similar result revealed that CMT7364/5-FU cell line was more resistant to 5-FU. In conclusion, a 5-FU-resistant canine mammary tumor cell line (CMT7364/5-FU) was successfully established, it can serve as a good model for researching the mechanism of MDR and screening effective agents to reverse drug resistance.

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2017
• Tom: 20
• Numer: 1
• Opis fizyczny: p.103-110,fig.,ref.

Twórcy

autor

Zhou B.

• Clinical Department, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China

autor

Zhang D.

• Clinical Department, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China

autor

Pei S.M.

• Clinical Department, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China

autor

Zhang K.

• Clinical Department, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China

autor

Du H.C.

• Clinical Department, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China

autor

Jin Y.P.

• Clinical Department, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China

autor

Lin D.G.

• Clinical Department, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China

Bibliografia

• Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58: 5337-5339.
• Bostedt H, Tammer I (1995) Prognosis of tumors of the canine mammary-gland-a retrospective study. Praktische Tierarzt 76: 921-924.
• Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522-527.
• Chen SY, Hu SS, Dong Q, Cai JX, Zhang WP, Sun JY, Wang TT, Xie J, He HR, Xing JF, Lu J, Dong YL (2013) Establishment of Paclitaxel-resistant Breast Cancer Cell Line and Nude Mice Models, and Underlying Multidrug Resistance Mechanisms in Vitro and in Vivo. Asian Pac J Cancer Prev 14: 6135-6140.
• Choi CH (2005) ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5: 30.
• Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358.
• Doyle LA, Yang WD, Abruzzo LV, Krogmann T, Gao YM, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Nat Acad Sci USA 95: 15665-15670.
• Griffin J, Fletcher N, Clemence R, Blanchflower S, Brayden DJ (2005) Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J Vet Pharmacol Ther 28: 257-265.
• Honscha KU, Schirmer A, Reischauer A, Schoon HA, Einspanier A, Gaebel G (2009) Expression of ABC-Transport Proteins in Canine Mammary Cancer: Consequences for Chemotherapy. Reprod Domest Anim 44: 218-223.
• Ikeda R, Vermeulen LC, Lau E, Jiang Z, Pomplun M, Kolesar JM (2010) Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells. Mol Med Rep 3: 1031-1034.
• Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, Saya H, Nagano O (2010) CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 101: 673-678.
• Iwasaki I, Sugiyama H, Kanazawa S, Hemmi H (2002) Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles. Cancer Chemother Pharmacol 49: 438-444.
• Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162.
• Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A (2001) Adjuvant post-perative chemotherapy in bitches with mammary cancer. J Vet Med A Physiol Pathol Clin Med 48: 85-96.
• Kessel D, Botteril V, Wodinsky I (1968) Uptake and Retention of Daunomycin by Mouse Leukemic Cells as Factors in Drug Response. Cancer Res 28: 938-941.
• Krol M, Pawlowski KM, Majchrzak K, Mucha J, Motyl T (2014) Canine mammary carcinoma cell line are resistant to chemosensitizers: verapamil and cyclosporin A. Pol J Vet Sci 17: 9-17.
• Kurzman ID, Gilbertson SR (1986) Prognostic factors in canine mammary tumors. Semin Vet Med Surg (Small Anim) 1: 25-32.
• Lage H (2008) An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 65: 3145-3167.
• Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
• Mealey KL (2012) ABCG2 transporter: therapeutic and physiologic implications in veterinary species. J Vet Pharmacol Ther 35: 105-112.
• Miyake K, Mickley L, Litman T, Zhan ZR, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59: 8-13.
• Moore N, Houghton J, Lyle S (2012) Slow-Cycling Therapy-Resistant Cancer Cells. Stem Cells Dev 21: 1822-1830.
• Nakaichi M, Takeshita Y, Okuda M, Nakamoto Y, Itamoto K, Une S, Sasaki N, Kadosawa T, Takahashi T, Taura Y (2007) Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines. J Vet Med Sci 69: 111-115.
• Oguri T, Bessho Y, Achiwa H, Ozasa H, Maeno K, Maeda H, Sato S, Ueda R (2007) MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther 6: 122-127.
• Okugawa K, Kobayashi H, Hirakawa T, Sonoda T, Ogura T, Nakano H (2004) In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo. J Cancer Res Clin Oncol 130: 178-186.
• Pawlowski KM, Mucha J, Majchrzak K, Motyl T, Krol M (2013) Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells. BMC Vet Res 9: 119-129.
• Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W, Dantzig AH (2005) The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 4: 855-863.
• Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Koerbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Paetzold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, Hoth M, Bastian BC, Vogt T, Herlyn M (2013) Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1B (high) Cells. Cancer Cell 23: 811-825.
• Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung NS, Lim SJ, Park JG (2005) Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 65: 3162-3170.
• Snow K, Judd W (1991) Characterisation of adriamycin- and amsacrine-resistant human leukaemic t cell lines. Bri J Cancer 63: 17-28.
• Sosnik A (2013) Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review. Adv Drug Deliv Rev 65: 1828-1851.
• Stratmann N, Failing K, Richter A, Wehrend A (2008) Mammary tumor recurrence in bitches after regional mastectomy. Vet Surg 37: 82-86.
• Sylvester P W (2011) Optimization of the Tetrazolium Dye (MTT) Colorimetric Assay for Cellular Growth and Viability. Drug Design and Discovery 716: 157-168.
• Thu Phuong T, Kim H, Choi J, Na M, Jeong H (2013) Reversal of P-glycoprotein-mediated multidrug resistance is induced by mollugin in MCF-7/adriamycin cells. Phytomedicine 20: 622-631.
• Tomiyasu H, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H (2014) Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients. Vet J 199: 103-109.
• Wey N, Kohn B, Gutberlet K, Rudolph R, Brunnberg L (1999) Mammary tumours in the bitch: clinical follow-up study (1995-1997). Kleintierpraxis 44: 565.
• Zandvliet M, Teske E, Chapuis T, Fink-Gremmels J, Schrickx JA (2013) Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein. J Vet Pharmacol Ther 36: 583-587.
• Zhang Y, Zhou T, Duan J, Xiao Z, Li G, Xu F (2013) Inhibition of P-glycoprotein and Glutathione S-transferase-pi mediated resistance by fluoxetine in MCF-7/ADM cells. Biomed Pharmacother 67: 757-762.

Identyfikatory

DOI

10.1515/pjvs-2017-0014